[{"id":"156d54c5-8d8f-476f-89e1-cf5c28672101","acronym":"","url":"https://clinicaltrials.gov/study/NCT05098327","created_at":"2021-10-28T17:56:21.946Z","updated_at":"2024-07-02T16:35:39.988Z","phase":"Phase 3","brief_title":"Pioglitazone and Insulin Resistance in ADT","source_id_and_acronym":"NCT05098327","lead_sponsor":"State University of New York at Buffalo","biomarkers":" AKT2 • IRS1 • TLR4 • MAPK8 • SOCS3","pipe":"","alterations":" ","tags":["AKT2 • IRS1 • TLR4 • MAPK8 • SOCS3"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 08/01/2021","start_date":" 08/01/2021","primary_txt":" Primary completion: 03/31/2023","primary_completion_date":" 03/31/2023","study_txt":" Completion: 03/31/2023","study_completion_date":" 03/31/2023","last_update_posted":"2023-08-15"},{"id":"e20d140c-2937-4561-a913-76a4c61c5fbd","acronym":"","url":"https://clinicaltrials.gov/study/NCT01711632","created_at":"2021-01-17T18:01:40.116Z","updated_at":"2024-07-02T16:35:41.371Z","phase":"Phase 2","brief_title":"BRAF Inhibitor, Vemurafenib, in Patients With Relapsed or Refractory Hairy Cell Leukemia","source_id_and_acronym":"NCT01711632","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" MAPK8","pipe":" | ","alterations":" RAS mutation","tags":["MAPK8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zelboraf (vemurafenib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 36","initiation":"Initiation: 10/01/2012","start_date":" 10/01/2012","primary_txt":" Primary completion: 10/01/2025","primary_completion_date":" 10/01/2025","study_txt":" Completion: 10/01/2025","study_completion_date":" 10/01/2025","last_update_posted":"2023-08-01"}]